Gentian Diagnostics ASA

Remuneration Information • Dec 4, 2020

Mandatory notification of trade

Mandatory notification of trade

Moss, 04 December 2020

Reference is made to the stock exchange release 04 December 2020 regarding the Employee Share Purchase Program. The Board of Gentian Diagnostics has resolved to issue 9,171 shares to employees at an issue price of NOK 50.38 per share.

Also, reference is made to the annual general meeting 28 May 2019 where a statement of remuneration to key personnel was given. In accordance with this statement the board of Gentian Diagnostics AS has allocated a total of 150,000 options to key employees under the existing option program.

The following number of shares and options have been allocated to primary insiders of Gentian Diagnostics AS:

Hilja Ibert, Chief Executive Officer: 397 shares. Following the allocations Ms. Ibert hold 6,525 shares and 279,924 options in the Company.

Njaal Kind, Group Chief Financial Officer: 397 shares and 40,000 options. Following the allocations Mr. Kind hold 20,712 shares and 114,991 options in the Company.

Erling Sundrehagen, Chief Scientific Officer: 50,000 options. Following the allocation Mr. Sundrehagen and related parties hold 184,083 shares and 100,000 options in the Company.

Torsten Knüttel, Vice President R&D: 397 shares. Following the allocation Mr. Knüttel hold 712 shares and 10,000 options in the Company.

Jack Andreassen, Vice President Business Development: 397 shares and 20,000 options. Following the allocation Mr. Andreassen hold 3,972 shares and 20,000 options in the Company.

Julie Gryga, Chief Financial Officer Gentian AS: 397 shares. Following the allocation Ms. Gryga hold 627 shares in the Company.

The exercise price for the options granted is NOK 62.88 being the average volume-weighted share price on the Oslo Stock Exchange for the past 10 trading days prior to 20 November. The right to exercise the options is vested over a period of 3 years, with 1/3 of the options vesting by the end of each year as follows: (i) 1/3 of the options granted, no earlier than 2 years after the allocation date (ii) 1/3 of the options granted, no earlier than 3 years after the allocation date (iii) 1/3 of the options granted, no earlier than 4 years after the allocation date.

For further information, please contact:

Hilja Ibert

CEO, Gentian Diagnostics

E-mail: hilja.ibert@gentian.no

Cell Phone: +47 919 05 242

Njaal Kind

CFO, Gentian Diagnostics

E-mail: njaal.kind@gentian.no

Cell Phone. +47 919 06 525